Transcription Factor FOXA1 Facilitates Glycolysis and Proliferation of Lung Adenocarcinoma via Activation of TEX19
- PMID: 37606876
- DOI: 10.1007/s12033-023-00848-2
Transcription Factor FOXA1 Facilitates Glycolysis and Proliferation of Lung Adenocarcinoma via Activation of TEX19
Abstract
Glycolysis is a shared feature in various cancers including lung adenocarcinoma (LUAD). Testis Expressed 19 (TEX19) is correlated with cancer progression. But its effect on LUAD remains an unanswered question. The focus of our study was primarily to investigate how TEX19 works exactly in LUAD. We first downloaded mRNA data from TCGA-LUAD and performed differential expression analysis. Then, we performed a Kaplan-Meier analysis to analyze the relationship between mRNA expression and patients' prognoses. hTFtarget database was utilized for the prediction of upstream transcription factors of mRNA. Next, qRT-PCR was employed for detecting TEX19 and Forkhead box A1 (FOXA1) expression. Western blot was adopted to detect the expression of glycolysis-related proteins. We also used CCK-8, colony formation, and flow cytometry assays to detect cell viability, proliferation, and apoptosis. Seahorse XF Extracellular Flux Analyzers were introduced to analyze extracellular acidification rate (ECAR) and oxygen consumption rate (OCR). Detection kits were used to detect pyruvate, lactate, citric acid, and malic acid. TEX19 was highly expressed in LUAD tissues. Real-time quantitative PCR (qRT-PCR) assay showed that TEX19 was significantly overexpressed in LUAD cell lines compared with normal bronchial epithelial cells BEAS-2B. Knockdown of TEX19 remarkably inhibited cell activity and proliferation, and promoted cell apoptosis, TEX19 was enriched in the glycolytic pathway. Meanwhile, the knockdown of TEX19 significantly hampered the contents of pyruvate, lactate, citric acid, and malic acid. The bioinformatics analysis, dual luciferase reporter experiment, and chromatin immunoprecipitation (ChIP) assay showed that FOXA1 was bound with TEX19. FOXA1 had a high expression level in LUAD. The rescue assay demonstrated that FOXA1, by activating TEX19 expression, enhanced glycolysis and proliferation and inhibited apoptosis of LUAD cells. In summary, FOXA1 promoted glycolysis and proliferation of LUAD cells by activating TEX19. This result can provide a theoretical basis for future research on LUAD.
Keywords: FOXA1; Glycolysis; LUAD; Proliferation; TEX19.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
FOXA1/UBE2T Inhibits CD8+T Cell Activity by Inducing Mediates Glycolysis in Lung Adenocarcinoma.Front Biosci (Landmark Ed). 2024 Apr 1;29(4):134. doi: 10.31083/j.fbl2904134. Front Biosci (Landmark Ed). 2024. PMID: 38682180
-
S1PR1 suppresses lung adenocarcinoma progression through p-STAT1/miR-30c-5 p/FOXA1 pathway.J Exp Clin Cancer Res. 2024 Nov 18;43(1):304. doi: 10.1186/s13046-024-03230-5. J Exp Clin Cancer Res. 2024. PMID: 39551792 Free PMC article.
-
FOXA1 activates NOLC1 transcription through NOTCH pathway to promote cell stemness in lung adenocarcinoma.Kaohsiung J Med Sci. 2025 Feb;41(2):e12930. doi: 10.1002/kjm2.12930. Epub 2025 Jan 10. Kaohsiung J Med Sci. 2025. PMID: 39789998 Free PMC article.
-
The transcription factor FOXA1 upregulates PYCR1-mediated autophagy to suppress antitumor immunity in lung adenocarcinoma.Cancer Immunol Immunother. 2025 Aug 23;74(9):290. doi: 10.1007/s00262-025-04144-7. Cancer Immunol Immunother. 2025. PMID: 40848149 Free PMC article.
-
[GINS1 Enhances Glycolysis, Proliferation and Metastasis in Lung Adenocarcinoma Cells by Activating the Notch/PI3K/AKT/mTORC1 Signaling Pathway].Zhongguo Fei Ai Za Zhi. 2024 Oct 20;27(10):735-744. doi: 10.3779/j.issn.1009-3419.2024.101.27. Zhongguo Fei Ai Za Zhi. 2024. PMID: 39631830 Free PMC article. Chinese.
Cited by
-
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.Aging (Albany NY). 2024 Aug 28;16(17):12392-12413. doi: 10.18632/aging.206096. Epub 2024 Aug 28. Aging (Albany NY). 2024. PMID: 39207452 Free PMC article.
-
In Silico Analysis Uncovers FOXA1 as a Potential Biomarker for Predicting Neoadjuvant Chemotherapy Response in Fine-Needle Aspiration Biopsies.J Cancer. 2024 Sep 30;15(18):6052-6072. doi: 10.7150/jca.101901. eCollection 2024. J Cancer. 2024. PMID: 39440050 Free PMC article.
References
-
- Sung, H., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
-
- Li, Y., et al. (2021). RNA m(6)A reader YTHDF2 facilitates lung adenocarcinoma cell proliferation and metastasis by targeting the AXIN1/Wnt/beta-catenin signaling. Cell Death and Disease, 12, 479. https://doi.org/10.1038/s41419-021-03763-z - DOI - PubMed - PMC
-
- Liu, X. S., et al. (2021). NPM1 is a prognostic biomarker involved in immune infiltration of lung adenocarcinoma and associated with m6A modification and glycolysis. Frontiers in Immunology, 12, 724741. https://doi.org/10.3389/fimmu.2021.724741 - DOI - PubMed - PMC
-
- Nooreldeen, R., & Bach, H. (2021). Current and future development in lung cancer diagnosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22168661 - DOI - PubMed - PMC
-
- Duma, N., Santana-Davila, R., & Molina, J. R. (2019). Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment. Mayo Clinic Proceedings, 94, 1623–1640. https://doi.org/10.1016/j.mayocp.2019.01.013 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical